Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
Notified -
Globe Newswire9-12-2025, 20:00
Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City 7-05-2025, 18:00